... Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium.
News
- Celcuity (CELC) Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with ...
- Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in ... - BioSpace
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or ...
- Texas state court throws out lawsuit against San Antonio doctor who violated abortion law
Dr. Alan Braid, abortion provider and owner of Alamo Women's Reproductive Services in San Antonio, sits in his office for a portrait on June 14, 2022.
- Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 ...
Active biotech and pharma companies in the markets this week include ... at the San Antonio Breast Cancer Symposium – Oncolytics Biotech® Chinese ...
- Duration of Prior CDK4/6 Inhibitor Treatment Tied to PFS With Elacestrant
... rates,” said Virginia Kaklamani, MD, of UT Health San Antonio, when presenting the results at the San Antonio Breast Cancer Symposium 2022.